| About NicOx | |||
| Products | |||
|
Naproxcinod NCX 6560 Full portfolio |
|||
| Maximizing portfolio | |||
| Co-development Research alliances Technology |
|||
| People | |||
|
Board of Directors Management Team Contacts Careers |
|||
| Investor & media | |||
| Press releases Investor relations Fact file Financials Corporate governance "Informations Réglementées" Conferences |
|||
| Home | |||
| Directions to NicOx Site en français |
|||
 |
Jean-Luc Bélingard - President and CEO of the Ipsen Group | ||
|
|
|||
 Jean-Luc
Bélingard is, since January 2002, President
and CEO of the Ipsen Group, an independent
European pharmaceutical company which
specialises in oncology, endocrinology and
neuromuscular disorders.Jean-Luc Belingard, 57, is a graduate from Hautes Etudes Commerciales, a leading French business school, and holds an MBA from Cornell University. He has spent the past 28 years in the pharmaceutical industry working with Merck & Co and Roche, where he was member of the Corporate Executive Committee and CEO of Roche Diagnostics. More recently, Mr. Bélingard joined Pierre Fabre in 1999 as Vice Chairman and CEO and was appointed CEO of BioMérieux-Pierre Fabre in 2000. Jean-Luc Bélingard sits on the Board of Celera Genomics, Laboratory Corporation of America, Exonhit Therapeutics and Inserm. |
|||